Menopausal and other perimenopausal disorders. Menopausal and female climacteric states
Conditions
Interventions
Intervention 1: Intervention group: Sertraline (50-200 milligram per day) besides vitagnus (one tablet a day) for six weeks. Intervention 2: Control group: Sertraline (in the dose of 50-200 milligram
Treatment - Drugs
Intervention group: Sertraline (50-200 milligram per day) besides vitagnus (one tablet a day) for six weeks
Control group: Sertraline (in the dose of 50-200 milligram per day)
Sponsors
Vice Chancellor for research of Babol University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: The patients who have been menopaused at least two years ago; Depression (the score more than 16 in Beck Depression Scale); The patient´s desire to participate in the study Exclusion criteria: The history of elevated mood; Psychosis; Severe suicidal thoughts; The history of renal disorders; The history of hepatic disorders
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient´s depressive condition. Timepoint: 3th and 6th weeks after treatment. Method of measurement: Beck Depression Scale.;Menopausal signs. Timepoint: 3th and 6th weeks after treatment. Method of measurement: Menopausal Rating Scale (Kapperman Scale). | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug reaction. Timepoint: 3rd and 6th weeks after treatment. Method of measurement: Interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSussan Moudi, MD
Babol University of Medical Sciences
Outcome results
None listed